GlassScriptPhysician profile
Bilal Mian
NPI 1700825999
$6,170.11
in general payments reported to CMS, 2019-2025
43 companies · $1,015 in 2025
The $1,015 reported for 2025 was more than what 88% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $878 · 2020: $507 · 2021: $763 · 2022: $836 · 2023: $1,084 · 2024: $1,088 · 2025: $1,015.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,187.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,187.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $847.64 | 2021-2025 | |
| Ucb, INC. | $736.42 | 2019-2025 | Briviact |
| Novartis Pharmaceuticals Corporation | $685.84 | 2019-2025 | |
| Eisai INC. | $578.78 | 2019-2025 | |
| Sk Life Science, INC. | $399.55 | 2020-2025 | |
| Teva Pharmaceuticals USA, INC. | $291.01 | 2019-2024 | Austedo Xr, Austedo, Ajovy |
| Pfizer INC. | $285.17 | 2021-2025 | |
| Lilly USA, LLC | $268.22 | 2019-2025 | Amyvid, Kisunla, Emgality |
| Amgen INC. | $229.63 | 2019-2023 | Aimovig |
| Biogen, INC. | $191.78 | 2019-2023 | Tysabri, Vumerity |
| Neurelis, INC. | $146.73 | 2021-2025 | Valtoco |
| Supernus Pharmaceuticals, INC. | $142.78 | 2019-2020 | |
| Adamas Pharmaceuticals, INC. | $119.29 | 2019-2021 | |
| Argenx US, INC. | $100.73 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Biohaven Pharmaceuticals, INC. | $81.90 | 2021 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bilal Mian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.